Edition:
United States

Recordati Industria Chimica e Farmaceutica SpA (RECI.MI)

RECI.MI on Milan Stock Exchange

35.18EUR
29 May 2017
Change (% chg)

-- (--)
Prev Close
€35.18
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
507,659
52-wk High
€36.76
52-wk Low
€24.24

RECI.MI

Chart for RECI.MI

About

Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central... (more)

Overall

Beta: 0.53
Market Cap(Mil.): €7,551.51
Shares Outstanding(Mil.): 209.13
Dividend: 0.35
Yield (%): 1.94

Financials

  RECI.MI Industry Sector
P/E (TTM): 30.17 14.27 17.41
EPS (TTM): 1.20 -- --
ROI: 19.60 -7.17 -5.42
ROE: 26.18 -6.63 -4.68

AstraZeneca sells aging beta-blocker to Recordati for $300 million

LONDON AstraZeneca has sold the European rights to its aging beta-blocker heart drug Seloken to Italy's Recordati for $300 million, as part of a continuing drive by the British drugmaker to spin off non-core assets.

May 22 2017

BRIEF-Recordati acquires from AstraZeneca European rights to Metoprolol based products

May 22 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA:

May 22 2017

BRIEF-Recordati Rare Diseases buys North American marketing rights to Cystadane

April 13 Recordati Industria Chimica e Farmaceutica SpA:

Apr 13 2017

BRIEF-Recordati incorporates unit Recordati SA Chemical and Pharmaceutical Company

March 2 Recordati Industria Chimica e Farmaceutica SpA:

Mar 02 2017

BRIEF-Italy's Recordati sees 2019 sales at around 1.45 bln euros

* sees 2019 sales at around 1.45 billion euros Source text for Eikon: Further company coverage: (Reporting by Milan newsroom)

Feb 09 2017

More From Around the Web

Earnings vs. Estimates